

Name of Sub-Committee:	Research & Innovation Sub-Committee
Chair of Sub-Committee:	Professor Philip Kloer, Medical Director/Deputy Chief Executive
Reporting Period:	Meeting held on 18 th July 2022

Key Decisions and Matters Considered by the Sub-Committee:

The Research & Innovation Sub-Committee (R&ISC) has not fully met since the last People, Organisational Development and Culture Committee (PODCC) meeting. The purpose of this report is to provide PODCC with an update on Research & Development (R&D) and Innovation activities, quality assurance and risk, and the financial position for assurance. The report is based on meetings and decisions taken at the:

- Research and Development Senior Management Team (20th June and 18th July 2022); and
- TriTech Management Group (27th June and 25th July 2022)

Research & Development

- The Year 2 strategy action plan and team objectives have been agreed. Progress will be monitored at monthly Senior Management Team meetings and reported quarterly to the R&ISC.
- 19 studies have been opened since the last report- a variety of portfolio / non portfolio and commercial
- Recruitment continues (37 recruiting studies, total recruits to date for 2022-23 = 287 across all sites Health & Care Research Wales (HCRW) data). Performance key performance indicators (KPIs) for HCRW are on target. HDdUHB are currently best in Wales for Recruiting to Time & Target KPI - 71% for portfolio studies.
- Phase One of the commissioned BioBank feasibility work is complete. The company undertaking the work (Trustech) has now started developing a fully costed business case for the preferred option six (Developing the West Wales Bioresource Centre) alongside option one (Stop/Exit), which is due to report to R&ISC October 2022.
- Training on the BioBank sample tracking system (LIMBUS) is now complete, with Prince Philip Hospital (PPH) and Glangwili General Hospital (GGH) now fully compliant. Withybush General Hospital (WGH) and Bronglais General Hospital (BGH) will receive full training on the system when they have freezer capacity fully in place.
- Relocation of the BGH research delivery team to a new clinical research facility at Ty Aeron has been agreed. Detailed plans for essential remedial works are being costed and will be presented to the next R&ISC meeting in September 2022. This will mean that the UHB has dedicated clinical trial facilities at PPH, GGH, and BGH, with only WGH outstanding.

Innovation

- The R&ISC held an extraordinary meeting on 18th July 2022 to approve the TriTech Business Plan. The TriTech business plan is on the agenda at the August PODCC meeting.
- New terms of reference for the Trittech and Innovation Group and the Senior Innovation and Trittech Operations Team are being submitted to R&ISC for approval at its September 2022 meeting.
- A new Project Development and Approval Pathway has been developed to improve governance and decision making within Innovation & Trittech.
- There have been 5 new Research & Innovation grant applications by the Development team since the last PODCC meeting.

- There have been 2 notifications of successful funding bids.
 - G:DATA, developing a game to aid Alzheimer's Disease diagnosis, led by Simon Gerhard with Ascentys funded by Innovate UK
 - Creative Development Prescribing led by Kathryn Lambert funded by Arts Council of Wales
 - There are 3 Bevan planned care projects which have been confirmed
 - Haematology - Project lead Rhian Fuge
 - Prehab/Reablement in elective surgery - Project lead Jason Bennett (Pembrokeshire County Council)
 - Borth Integrated Health and Care - Project lead Dr Sue Fish
- There are 3 Health Hack projects confirmed with contracting in progress:
 - DigniLift - Lead Mark Barnard with GX
 - Diabetes remission - Lead Nerys Frater with Fusion
 - Protecting health through social care – Lead Claire Hurlin with Haelu
- There is 1 Bevan Cancer Innovation and Improvement Programme Project in progress led by Rachel Lewis looking at Prehabilitation signposting
- There are 2 new Tritech Institute projects since the last PODCC meeting, Amgen and G:DATA.

Quality Assurance/Risk

R&D Department

- Research Quality Management Group (RQMG) – no issues have been reported since the last PODCC.
- No new triggered audits or monitoring visits have taken place since the last PODCC.
- R&D Department Risk Register:
 - There are no identified risks with increased scores and no new risks to report. **Risk 757, 1175 & 1034** have been closed
 - **Risk 1035** Relocation of the BGH delivery team to Ty Aeron at BGH has been agreed. Detailed plans for essential remedial works are being costed and will be reported at R&ISC September 2022
 - **Risk 1036** WGH delivery team are now in new interim accommodation (adjacent to Chemotherapy Discharge Lounge), plans to relocate to longer term accommodation are in progress
 - **Risk 1160 Directorate Level** – research leadership, score 12 unchanged. A review of the impact of management action against this risk is currently being undertaken.

Tritech Institute & Innovation

- Tritech Internal audit HDdUHB-2122-40 - All actions have been addressed, awaiting follow up Internal audit in Q3/4 2022.
- There are no triggered audits or monitoring visits to report on Innovation projects.
- ISO 1348 Quality Management system with BSi has been achieved, no issues to raise.

Tritech Institute Risk Register

- **1142** and **1158** have been closed (pending agreement from R&ISC).
- **1156** relates to Tritech generating sufficient income – M3 forecast is £8k surplus at year end.

Financial Position

R&D Department

- HCRW All Wales Research Delivery Funding for 22/23 was confirmed as £1,197,660
- M3 Finance Summary has been noted and accepted, the Research Delivery Total showing £6,456 overspend, this variance has been accounted for and HCRW have agreed to cover. The HCRW needs based spending plan forecast 23/24 has been submitted 18th July 2022. The capacity building account currently has a positive balance of £194,365.

Tritech Institute

- M3 Finance Summary has been noted and accepted as a surplus of £8,079.

Matters Requiring People, Organisational Development & Culture Committee Level Consideration or Approval:

- Approval of the TriTech Business Plan (on the agenda for PODCC meeting August 2022)

Risks / Matters of Concern:

RISK 1160 (Directorate Risk)			
TOPIC	CAUSE	SCORE	ACTIONS
There is a risk of a decreasing research portfolio, both in amount as well as diversity	This is caused by a lack of research leadership across HDdUHB (staff able to act as Principal Investigators)	12	A competitive process has been concluded that has led to the appointment of three new clinical leads for research. (Oncology, Women's Health, and the GGH site). The arrangements will be tested over the next 6 months before deciding whether to extend to other sites and specialities. Review 15/08/22.
			A colorectal cancer surgeon has two sessions protected for research, initially supported by a grant (Moondance Cancer Initiative), however with HDdUHB commitment to continue to support if successful. A research midwife with three days a week for developing the midwifery research portfolio, funded by R&D. Review 15/08/22.

Planned Sub-Committee Business for the Next Reporting Period:

Future Reporting:

In addition to routine business, the Research & Innovation Sub-Committee will receive reports on:

- A 'Look Forward' report for Year 2 of the Research & Innovation Strategy.
- A draft Power BI dashboard for R&D development, quality assurance, and finance metrics.
- In response to an action from PODCC (04/04/22) it is proposed the Research & Innovation Sub-Committee report will be extended to include items from University Partnerships meetings where key decisions and matters are to be considered.

Date of Next Meeting:

Monday, 12th September 2022